NEW YORK (GenomeWeb News) – EMD Biosciences, part of Merck KGaA’s Performance and Life Science Chemicals division, has signed an exclusive license and supply agreement with Dendritic Nanotechnologies for siRNA and DNA transfection reagents, the companies said today.
Under the terms of the agreement, DNT a US subsidiary of Australian firm Starpharma, will supply EMD Biosciences with its Priofect transfection reagents. EMD will market the reagents through its Novagen product line.
DNT retains full rights to all in vivo aspects of transfecting nucleic acids with the Priostar technology. Additional terms of the agreement, which includes royalties and milestone payments, were not disclosed.
According to DNT, PrioFect transfection reagents offer nanometer-size control, which will enable EMD to offer siRNA transfection reagents with sizes optimized for individual cell lines.